Premium
Pirfenidone reduces subchondral bone loss and fibrosis after murine knee cartilage injury
Author(s) -
Chan Deva D.,
Li Jun,
Luo Wei,
Predescu Dan N.,
Cole Brian J.,
Plaas Anna
Publication year - 2018
Publication title -
journal of orthopaedic research®
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.041
H-Index - 155
eISSN - 1554-527X
pISSN - 0736-0266
DOI - 10.1002/jor.23635
Subject(s) - pirfenidone , cartilage , medicine , fibrosis , inflammation , osteoarthritis , pathology , extracellular matrix , idiopathic pulmonary fibrosis , lung , anatomy , microbiology and biotechnology , biology , alternative medicine
Pirfenidone is an anti‐inflammatory and anti‐fibrotic drug that has shown efficacy in lung and kidney fibrosis. Because inflammation and fibrosis have been linked to the progression of osteoarthritis, we investigated the effects of oral Pirfenidone in a mouse model of cartilage injury, which results in chronic inflammation and joint‐wide fibrosis in mice that lack hyaluronan synthase 1 (Has1 −/− ) in comparison to wild‐type. Femoral cartilage was surgically injured in wild‐type and Has1 −/− mice, and Pirfenidone was administered in food starting after 3 days. At 4 weeks, Pirfenidone reduced the appearance, on micro‐computed tomography, of pitting in subchondral bone at, and cortical bone surrounding, the site of cartilage injury. This corresponded with a reduction in fibrotic tissue deposits as observed with gross joint surface photography. Pirfenidone resulted in significant recovery of trabecular bone parameters affected by joint injury in Has1 −/− mice, although the effect in wild‐type was less pronounced. Pirfenidone also increased Safranin‐O staining of growth plate cartilage after cartilage injury and sham operation in both genotypes. Taken together with the expression of selected extracellular matrix, inflammation, and fibrosis genes, these results indicate that Pirfenidone may confer chondrogenic and bone‐protective effects, although the well‐known anti‐fibrotic effects of Pirfenidone may occur earlier in the wound‐healing response than the time point examined in this study. Further investigations to identify the specific cell populations in the joint and signaling pathways that are responsive to Pirfenidone are warranted, as Pirfenidone and other anti‐fibrotic drugs may encourage tissue repair and prevent progression of post‐traumatic osteoarthritis. © 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:365–376, 2018.